Nautilus Biotechnology (NAUT) Return on Assets (2021)

Nautilus Biotechnology (NAUT) reported Return on Assets of 0.0% for Q4 2021, up 40.21% sequentially from 0.0% in Q3 2021.

Nautilus Biotechnology (NAUT) Return on Assets (2021) Analysis & Trends

Nautilus Biotechnology (NAUT) has 1 years of Return on Assets data on file, last reported at 0.0% in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-0.69%
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-0.01%
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-0.80%
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	0.00%
10	Nautilus Biotechnology	224.14 Mn	224.14 Mn	-	-

Download Data